Edgewise Therapeutics

United States
Santa Maria, California, United States, 80303

Company profile

Edgewise Therapeutics company profile

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Guided by its holistic drug discovery approach to targeting the muscle as an organ, Edgewise has combined its foundational expertise in muscle biology and small molecule engineering to build its proprietary, muscle focused drug discovery platform. Edgewise’s platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases.

Business identity

Contact email
[email protected]
Phone number
720.262.7002
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$1M-$10M
Founded
2017-01-01

Headquarters

Postal code
80303
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
6
Total equity funding
$738.5M
Last funding
Post IPO Equity / $200M / 2025-04-02
Last equity funding
Post IPO Equity / $200M
Investors
25
Lead investors
3
Founders
3
Articles
206
Exited on
2021-03-26

Founders and investors

Founders

Alan RussellBadreddin EdrisPeter Thompson

Lead investors

Novo HoldingsU.S. Venture PartnersViking Global Investors

Investors

Cormorant Asset ManagementFrazier Life SciencesJanus Henderson InvestorsRA Capital ManagementWellington Management